Drug Trial Radar · NCT04970901
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
154
Actual
Start
Jun 17, 2022
Primary completion
Mar 31, 2027
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- ADC Therapeutics S.A.Industry
- Sponsor type
- Industry
- First posted
- Jul 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
Conditions
- B-Cell Non-Hodgkin Lymphoma
- Relapsed B-Cell Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
Loncastuximab TesirineDrug
Intravenous (IV) infusion
Polatuzumab VedotinDrug
IV infusion
GlofitamabDrug
IV infusion
MosunetuzumabDrug
Subcutaneous (SC) injection
ObinutuzumabDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)Time frame: Day 1 to Day 21 of Cycle 1, where a cycle is 21 days
- Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)Time frame: Up to approximately 2 years for Arm C and 3 years for Arms E and F
- Number of Participants Who Experience an Adverse Event (AE) Leading to Dose DelayTime frame: Up to approximately 1 year
- Number of Participants Who Experience an Adverse Event (AE) Leading to Dose InterruptionTime frame: Up to approximately 1 year
- Number of Participants Who Experience an Adverse Event (AE) Leading to Dose ReductionTime frame: Up to approximately 1 year
- Number of Participants Who Experience a Clinically Significant Change from Baseline in Safety Laboratory MeasurementsTime frame: Baseline up to approximately 1 year
- Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital SignsTime frame: Baseline up to approximately 1 year
- Number of Participants Who Experience a Clinically Significant Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance StatusTime frame: Baseline up to approximately 1 year
- Number of Participants Who Experience a Clinically Significant Change from Baseline in 12-Lead Electrocardiogram (ECG) MeasurementsTime frame: Baseline up to approximately 1 year
Locations
40 sites in 6 countries. Site status is shown where the registry gives one.
University of California San Francisco - Fresno Center for Medical Education and Research
Clovis, California
Scripps Health - Prebys Cancer Center
San Diego, California
Sylvester Comprehensive Cancer Center
Miami, Florida
Miami Cancer Institute
Miami, Florida
Memorial Cancer Institute - Memorial Hospital West
Pembroke Pines, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
The Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia
Mission Cancer + Blood - Mission Cancer Foundation
Des Moines, Iowa
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Minnesota
Minneapolis, Minnesota
Columbia University Irving Medical Center
New York, New York
Cleveland Clinic Main Campus
Cleveland, Ohio
Oregon Health and Science University
Portland, Oregon
Penn Medicine - Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania
Allegheny Health Network - West Penn Hospital
Pittsburgh, Pennsylvania
Brown University Health - Rhode Island Hospital
Providence, Rhode Island
Hollings Cancer Center
Charleston, South Carolina
Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR)
Nashville, Tennessee
Baylor University Medical Center
Dallas, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Emily Couric Clinical Cancer Center
Charlottesville, Virginia
NEXT Virginia (Virginia Cancer Specialists)
Fairfax, Virginia
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin
Universitair Ziekenhuis Gent
Ghent, Belgium
Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne
Yvoir, Belgium
Fakultni nemocnice Ostrava
Ostrava, Czechia
Fakultní Nemocnice Královské Vinohrady
Prague, Czechia
Fakultni nemocnice v Motole
Prague, Czechia
Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII
Bergamo, Italy
Centro di Ricerche Cliniche - IRCCS Azienda Ospedaliero Universitaria di Bologna
Bologna, Italy
Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia
Brescia, Italy
Istituto Europeo di Oncologia
Milan, Italy
Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)
Barcelona, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Complejo Asistencial Universitario de Salamanca - Hospital Clínico
Salamanca, Spain
Hospital Universitari i Politècnic La Fe
Valencia, Spain
University College London Hospitals NHS Foundation Trust
London, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.